Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Disease Modification in Myelofibrosis: An Elusive Goal?
Pankit Vachhani, Srđan Verstovšek, Prithviraj Bose
Journal of Clinical Oncology (2022) Vol. 40, Iss. 11, pp. 1147-1154
Open Access | Times Cited: 18

Showing 18 citing articles:

Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy
Naveen Pemmaraju, Prithviraj Bose, Raajit K. Rampal, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2023) Vol. 64, Iss. 6, pp. 1063-1081
Open Access | Times Cited: 27
Moving toward disease modification in polycythemia vera
Jan Philipp Bewersdorf, Joan How, Lucia Masárová, et al.
Blood (2023) Vol. 142, Iss. 22, pp. 1859-1870
Closed Access | Times Cited: 15
Association of Myelofibrosis Phenotypes with Clinical Manifestations, Molecular Profiles, and Treatments
Helen T. Chifotides, Srđan Verstovšek, Prithviraj Bose
Cancers (2023) Vol. 15, Iss. 13, pp. 3331-3331
Open Access | Times Cited: 14
Survey of Clinical Practice in Chronic Myeloproliferative Neoplasms in Croatia: A Study by the MPN Working Group Party of the Croatian Cooperative Group for Hematologic Diseases (KROHEM)
Ivan Krečak, Marko Lucijanić, Rajko Kušec
Journal of Clinical Medicine (2025) Vol. 14, Iss. 5, pp. 1524-1524
Open Access
Myeloproliferative neoplasms in the adolescent and young adult population: A comprehensive review of the literature
Hannah Goulart, Lucia Masárová, Ruben A. Mesa, et al.
British Journal of Haematology (2024) Vol. 205, Iss. 1, pp. 48-60
Closed Access | Times Cited: 3
Cytopenic myelofibrosis: prevalence, relevance, and treatment
Pankit Vachhani, Srđan Verstovšek, Prithviraj Bose
Expert Opinion on Pharmacotherapy (2023) Vol. 24, Iss. 8, pp. 901-912
Closed Access | Times Cited: 8
SOHO State of the Art Updates and Next Questions: Novel Therapeutic Strategies in Development for Myelofibrosis
Helen T. Chifotides, Lucia Masárová, Srđan Verstovšek
Clinical Lymphoma Myeloma & Leukemia (2023) Vol. 23, Iss. 4, pp. 219-231
Open Access | Times Cited: 7
SOHO State of the Art Updates and Next Questions | Early Intervention in Myelofibrosis: Where Are We and Does It Matter?
Abdulraheem Yacoub, Nicole Twardowski, Alec Britt, et al.
Clinical Lymphoma Myeloma & Leukemia (2024) Vol. 24, Iss. 8, pp. 506-511
Open Access | Times Cited: 2
Lysine-Specific Demethylase 1 (LSD1/KDM1A) Inhibition as a Target for Disease Modification in Myelofibrosis
Harinder Gill
Cells (2022) Vol. 11, Iss. 13, pp. 2107-2107
Open Access | Times Cited: 10
Fedratinib, the first selective JAK2 inhibitor approved for treatment of myelofibrosis – an option beyond ruxolitinib
Chandan Saha, Claire Harrison
Expert Review of Hematology (2022) Vol. 15, Iss. 7, pp. 583-595
Closed Access | Times Cited: 9
Moving beyond ruxolitinib failure in myelofibrosis: evolving strategies for second line therapy
Prithviraj Bose, Andrew Kuykendall, Carole B. Miller, et al.
Expert Opinion on Pharmacotherapy (2023) Vol. 24, Iss. 9, pp. 1091-1100
Closed Access | Times Cited: 5
SOHO State of the Art Updates and Next Questions: Novel Therapies in Development for Myelofibrosis
Helen T. Chifotides, Prithviraj Bose, Lucia Masárová, et al.
Clinical Lymphoma Myeloma & Leukemia (2021) Vol. 22, Iss. 4, pp. 210-223
Closed Access | Times Cited: 11
Consistency of Spleen and Symptom Reduction Regardless of Cytopenia in Patients With Myelofibrosis Treated With Pacritinib
Nico Gagelmann, Prithviraj Bose, Vikas Gupta, et al.
Clinical Lymphoma Myeloma & Leukemia (2024) Vol. 24, Iss. 11, pp. 796-803
Open Access | Times Cited: 1
Momelotinib for the treatment of myelofibrosis
Prithviraj Bose
Blood (2024) Vol. 144, Iss. 7, pp. 708-713
Closed Access | Times Cited: 1
Emerging Treatment Options for Myelofibrosis: Focus on Anemia
Dahniel Sastow, Douglas Tremblay
Therapeutics and Clinical Risk Management (2023) Vol. Volume 19, pp. 535-547
Open Access | Times Cited: 2
SOHO State of the Art Updates and Next Questions | Choosing and Properly Using a JAK Inhibitor in Myelofibrosis
Michael J. Hochman, Colin A. Vale, Anthony M. Hunter
Clinical Lymphoma Myeloma & Leukemia (2024)
Closed Access
Investigational drugs in early phase trials for myelofibrosis
Sankalp Arora, Pankit Vachhani, Prithviraj Bose
Expert Opinion on Investigational Drugs (2024), pp. 1-14
Closed Access
A Novel Subtype of Myeloproliferative Neoplasms Driven by a MYC-Alarmin Axis
Nicole D. Vincelette, Xiaoqing Yu, Andrew Kuykendall, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 1
Page 1

Scroll to top